Stock comparison
Pro Medicus Limited
PME.AX$18.69BHealthcare Market cap, Sector
TransMedics Group
TMDX$3.06BHealthcare Market cap, Sector
Overall winner
Pro Medicus Limited
PME.AX 70 TMDX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
Fit scores by strategy
PME.AX7wins
0winsTMDX
78B
D51
90A
D57
98A
D52
100A
B80
84B
F44
91A
D50
96A
F43
Side-by-side metrics
| Metric | PME.AX | TMDX |
|---|---|---|
| Market cap | Winner: $18.69B | $3.06B |
| P/E (TTM) | 147.6x | 12.6x Winner |
| EV/EBIT | 106.8x | 23.4x Winner |
| ROIC (TTM) | Winner: 42.56% | 6.94% |
| Gross margin | Winner: 99.85% | 59.09% |
| Net margin | Winner: 54.12% | 27.04% |
| Revenue CAGR 5y | 31.61% | 111.5% Winner |
| EPS CAGR 5y | 37.34% | - |
| Debt / Equity | Winner: 0.0x | 1.7x |
| Dividend yield | - | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
PME.AX leads on
- Debt / Equity0.0xvs 1.7x+99%
- ROIC (TTM)42.56%vs 6.94%+84%
- Market cap$18.69Bvs $3.06B+84%
- Net margin54.12%vs 27.04%+50%
TMDX leads on
- P/E (TTM)12.6xvs 147.6x+91%
- EV/EBIT23.4xvs 106.8x+78%
- Revenue CAGR 5y111.5%vs 31.61%+72%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.